Market Newsdesk

December 2020 report highlights multi-terrain loaders, dozers, loaders, graders, trucks, and more

VANCOUVER, BC, Jan. 11, 2021 /PRNewswire/ – With its auctions 100% online due to COVID-19, Ritchie Bros. drew record buyer demand in 2020. As a result, the company’s latest Used Equipment Market Trends report is showing price inflation across all majority equipment categories. For example, U.S. truck tractor prices increased 8% over the same time period (three months ending December) in 2019.

The December 2020 Market Trends summary includes a deep dive into multi-terrain loader sales, the versatile machine used across nearly every industry. In the United States, 2020 has been a particularly strong year for multi-terrain loaders. In fact, in the first three quarters of 2020 (Jan – Sep), Ritchie Bros. sold 2,750+ multi-terrain loaders for US$64 million, which is just shy of total multi-terrain loader sales for 2019.   

“Used across industry, the versatile multi-terrain loader was in high demand in 2020, with a record number of units selling through our numerous sales channels,” said Doug Olive, Senior Vice President, Pricing, Ritchie Bros. “There are a number of factors that have contributed to this record-breaking year for multi-terrain loader sales, including an uptick in residential construction, rental company fleet renewals, landscaping projects, seasonal work, and more. In the past five years, Ritchie Bros. has sold 14,000 multi-terrain loaders for US$313 million!”

To learn more about equipment and truck prices, download the December version of the Ritchie Bros. Used Equipment Market Trends summary report at rbassetsolutions.com/market-trends-report. The December report also includes mix adjusted used pricing indices, including a comparison chart for the U.S. Ritchie Bros. Heavy Truck Price Index and U.S. Heavy Duty Truck shipments, plus a feature section on small construction highlights.

The Market Trends application is an independent part of the suite of services within Ritchie Bros. Asset Solutions (rbassetsolutions.com), which is a complete end-to-end asset management and disposition system. This cloud-based SaaS solution brings together a suite of tools and services to help customers better manage, analyze, and sell their assets. From any internet-enabled device, customers are able to access a complete inventory management system, data analytics and dashboards, branded e-commerce sites, and multiple external sales channels.

For more information about Market Trends, please email [email protected].

About Ritchie Bros.:

Established in 1958, Ritchie Bros. (NYSE and TSX: RBA) is a global asset management and disposition company, offering customers end-to-end solutions for buying and selling used heavy equipment, trucks and other assets. Operating in a number of sectors, including construction, transportation, agriculture, energy, oil and gas, mining, and forestry, the company’s selling channels include: Ritchie Bros. Auctioneers, the world’s largest industrial auctioneer offers live auction events with online bidding; IronPlanet, an online marketplace with featured weekly auctions and providing the exclusive IronClad Assurance® equipment condition certification; Marketplace-E, a controlled marketplace offering multiple price and timing options; Mascus, a leading European online equipment listing service; and Ritchie Bros. Private Treaty, offering privately negotiated sales. The company’s suite of multichannel sales solutions also includes Ritchie Bros. Asset Solutions, a complete end-to-end asset management and disposition system. Ritchie Bros. also offers sector-specific solutions including GovPlanet, TruckPlanet, and Kruse Energy, plus equipment financing and leasing through Ritchie Bros. Financial Services. For more information about Ritchie Bros., visit RitchieBros.com.

Photos and video for embedding in media stories are available at rbauction.com/media. 

View original content:http://www.prnewswire.com/news-releases/truck-tractors-and-heavy-equipment-prices-on-the-rise-according-to-ritchie-bros-latest-market-trends-report-301205033.html

SOURCE Ritchie Bros.

NEW YORK, Jan. 11, 2021 /PRNewswire/ — Shutterstock, Inc. (NYSE: SSTK), a leading global creative platform offering full-service solutions, high-quality content, and tools for brands, businesses and media companies, will report its fourth quarter and full year 2020 business and financial results on Thursday, February 11, 2021 before the market opens.

The company will host a conference call at 8:30 a.m. ET to discuss the results. The conference call can be accessed in the U.S. at (844) 634-1442 or outside the U.S. at (615) 247-0239 with the conference ID# 4294996. A live audio webcast of the call will also be available on Shutterstock’s website at http://investor.shutterstock.com.

Following completion of the call, a recorded replay of the webcast will be available in the investor relations section of Shutterstock’s website. A telephone replay of the call will also be available until February 18,2021 in the U.S. at (855) 859-2056 or outside the U.S. at (404) 537-3406 with the conference ID# 4294996.

About Shutterstock

Shutterstock, Inc. (NYSE: SSTK), directly and through its group subsidiaries, is a leading global provider of high-quality licensed photographs, vectors, illustrations, videos and music to businesses, marketing agencies and media organizations around the world. Working with its growing community of over one million contributors, Shutterstock adds hundreds of thousands of images each week, and currently has more than 350 million images and more than 20 million video clips available.

Headquartered in New York City, Shutterstock has offices around the world and customers in more than 150 countries. The company’s brands also include Bigstock, a value-oriented stock media offering; Shutterstock Studios, an end-to-end custom creative shop; Offset, a high-end image collection; PremiumBeat, a curated royalty-free music library; and Shutterstock Editorial, a premier source of editorial images and videos for the world’s media.

For more information, please visit www.shutterstock.com and follow Shutterstock on Twitter and on Facebook.

View original content to download multimedia:http://www.prnewswire.com/news-releases/shutterstock-to-report-fourth-quarter-and-full-year-2020-earnings-results-on-february-11-2021-301203647.html

SOURCE Shutterstock, Inc.

• Expected program value, including options, of more than US$275 million over next eight years

Tampa, Fla., Jan. 11, 2021 /PRNewswire/ – (NYSE: CAE) (TSX: CAE) – CAE today announced that the United States Air Force (USAF) awarded CAE USA a contract to continue providing comprehensive KC-135 training services.

The eight-year contract, awarded as a one-year base contract with seven additional one-year option periods, is valued at a total of more than US$275 million.

CAE USA became the prime contractor on the USAF KC-135 Training System program in 2010 and has now won the competitive recompete to continue delivering classroom and simulator training for KC-135 pilots and boom operators.  CAE USA will also continue to provide updates and upgrades to KC-135 training devices, including KC-135 operational flight trainers and boom operator trainers.  In addition, the KC-135 Training System contract now includes training support for the Air National Guard’s Boom Operator Simulator System (BOSS).  In total, CAE USA will support the training of more than 4,500 KC-135 crewmembers annually.

“CAE USA did an outstanding job supporting the U.S. Air Force on the KC-135 training program over the past decade, and we are extremely pleased to win the recompete competition and remain the KC-135 training partner,” said Ray Duquette, President and General Manager, CAE USA. 

CAE USA will be supported on the KC-135 Training System program by a team of industry partners, including Delaware Resource Group (DRG), Cardinal Point, FAAC, and CymSTAR.

“The KC-135 Stratotanker plays a vital role in the U.S. Air Force’s ability to deliver global reach, and we are honored to contribute to the training and readiness of the KC-135 aircrews who fly these essential tanker missions,” said Dan Gelston, Group President, Defense & Security, CAE. 

KC-135 Training System Site Background

CAE USA will deliver KC-135 aircrew training to USAF active-duty, Air National Guard and reserve crewmembers at 12 sites in the United States and internationally:

• Altus Air Force Base (AFB) in Oklahoma, which is the site of the formal training unit;
• Fairchild AFB, Washington;
• March Air Reserve Base (ARB), California;
• Scott AFB, Illinois;
• Grissom ARB, Indiana;
• MacDill AFB, Florida;
• General Mitchell Air National Guard Base (ANGB), Wisconsin;
• Rickenbacker ANGB, Ohio;
• Pittsburgh ANGB, Pennsylvania;
• Joint Base Pearl Harbor-Hickam, Hawaii;
• Kadena Air Base, Japan;
• Royal Air Force Base Mildenhall, United Kingdom.

In addition, the new KC-135 Training System contract includes training support for the Air National Guard KC-135 BOSS, which will be delivered at an additional 12 sites in the United States:

• Sioux City ANGB, Iowa;
• Lincoln ANGB, Nebraska;
• Forbes Field, Kansas;
• Phoenix ANGB, Arizona;
• Ronald Wright ANGB, Utah;
• Eielson AFB, Alaska;
• Bangor ANGB, Maine;
• McGuire AFB, New Jersey;
• Sumpter Smith Joint National Guard Base, Alabama;
• Selfridge ANGB, Michigan;
• McGee Tyson ANGB, Tennessee;
• Key Field, Mississippi.

KC-135 BOSS training support will also be provided at Joint Base Pearl Harbor; Pittsburgh ANGB; General Mitchell ANGB; and Rickenbacker ANGB.

About CAE Defense & Security

CAE’s Defense & Security business unit focuses on helping prepare our customers to develop and maintain the highest levels of mission readiness.  We are a world-class training and mission systems integrator offering a comprehensive portfolio of training and operational support solutions across the air, land, sea and public safety market segments.  We serve our global defense and security customers through regional operations in Canada; the United States/Latin America; Europe/Middle East; and Asia-Pacific, all of which leverage the full breadth of CAE’s capabilities, technologies and solutions.

About CAE

CAE is a high technology company, at the leading edge of digital immersion, providing solutions to make the world a safer place. Backed by a record of more than 70 years of industry firsts, we continue to reimagine the customer experience and revolutionize training and operational support solutions in civil aviation, defense and security, and healthcare. We are the partner of choice to customers worldwide who operate in complex, high-stakes and largely regulated environments, where successful outcomes are critical. Testament to our customers’ ongoing needs for our solutions, over 60 percent of CAE’s revenue is recurring in nature. We have the broadest global presence in our industry, with approximately 10,000 employees, 160 sites and training locations in over 35 countries. www.cae.com

Follow us on Twitter @CAE_Inc and @CAE_Defence
Facebook: www.facebook.com/cae.inc
LinkedIn: www.linkedin.com/company/cae

CAE USA recently won the recompete of the U.S. Air Force KC-135 Aircrew Training System contract and will continue providing training to more than 4,500 KC-135 crewmembers annually. 

View original content to download multimedia:http://www.prnewswire.com/news-releases/cae-usa-wins-competitive-recompete-of-us-air-force-kc-135-training-system-contract-301203575.html

SOURCE CAE INC.

LOS ANGELES, Jan. 11, 2021 /PRNewswire/ — Rexford Industrial Realty, Inc. (the “Company” or “Rexford Industrial”) (NYSE: REXR), a real estate investment trust (“REIT”) focused on creating value by investing in and operating industrial properties in Southern California infill markets, today announced operating results, transaction and capital markets activity for the fourth quarter and full year 2020.

“Rexford’s exceptional performance throughout 2020 demonstrates the strength of our strategy and team, focused on creating value by investing, improving and operating industrial property within infill Southern California, the world’s fourth largest industrial market and highest-demand, lowest-supply industrial property market in the nation,” stated Michael Frankel and Howard Schwimmer, Co-Chief Executive Officers of the Company.  “We are pleased to announce our team’s outstanding operating results for the fourth quarter and full year 2020, despite the circumstances surrounding the COVID-19 pandemic. In the fourth quarter we executed over 1.8 million square feet of new and renewal leases at strong leasing spreads representing 30% growth, demonstrating the continued intensity of tenant demand for our high-quality, irreplaceable industrial portfolio and our team’s entrepreneurial approach to asset management and customer service. Our full year acquisition volume of over $1.2 billion, with $875 million acquired during the fourth quarter, is a testament to our unparalleled sourcing model in which 75% of transactions were executed through off-market or lightly-marketed transactions. Our 2020 investments are expected to contribute $48 million of NOI in 2021, with this contribution expected to grow at a compounded average rate of approximately 8% over the next three years as we capitalize on value-creation opportunities, below-market leases and contractual embedded rent growth. Looking ahead, our pipeline of acquisition opportunities remains strong with approximately $140 million of new investments under LOI or contract and expected to close in the near-term. Our superior internal and external growth opportunities, highly differentiated and entrepreneurial business model and team, coupled with our low-leverage, fortress-like balance sheet position the Company to maximize cash flow growth and long-term shareholder value.”  

Operating Results:

Fourth quarter and full year 2020 leasing activity demonstrate strong tenant demand fundamentals within Rexford’s target Southern California infill markets.

 

In the fourth quarter, the Company executed approximately 900,000 square feet of leases that were previously scheduled to expire in 2021 at cash releasing spreads of 17.3%. As of December 31, 2020, lease expirations for the full year 2021 total 4.8 million rentable square feet, representing approximately 15% of total portfolio rentable square feet.  The mark-to-market on the remaining 2021 expiring leases is estimated to be approximately 17%.  At December 31, 2020, the Company’s Stabilized Same Property Portfolio occupancy was 98.2%.

Rent Collections Update:

As of January 8, 2021, the company has collected 97.3% of contractual fourth quarter billings, including 96.0% of the $3.35 million of fourth quarter Covid-19 related deferral repayment billings. Collections of contractual billings for the second and third quarter 2020 were 87.9% and 97.3%, respectively.

Transaction Activity:

During the fourth quarter, the Company completed 10 acquisitions representing 17 properties and 3.4 million square feet for an aggregate purchase price of $874.9 million.  Additionally, the Company sold one property for a sales price of $1.3 million. Fourth quarter acquisitions included two UPREIT transactions, whereby the Company issued 2.4 million operating partnership units (“OP Units”), representing $111.8 million of purchase price value.

During the full year of 2020, the Company completed 20 acquisitions representing 38 properties and 5.0 million square feet for an aggregate purchase price of $1.2 billion.  The estimated weighted average unlevered stabilized yield for 2020 acquisitions is 4.4%, with ongoing embedded cash flow growth projected into future periods.  Additionally, the Company sold four properties for an aggregate sales price of $45.5 million.  Full year acquisition activity included a total of three UPREIT transactions, whereby the Company issued 3.8 million OP Units, representing $179.3 million of purchase price value. 

Subsequent to year end, the Company acquired 15010 Don Julian Road, a 100% leased property located in the Los Angeles – San Gabriel Valley submarket, for $22.2 million or $46 per land square foot. At lease expiration in 2022, the Company plans to redevelop the 10.97 acre site into a 218,000 square foot newly constructed Class A warehouse/distribution facility, with an estimated unlevered stabilized yield of approximately 5.5%. The acquisition was funded using cash on hand.

Capital Markets Activity:

In November, the company completed its inaugural public bond offering of $400 million 2.125% senior notes due 2030 (the “Notes”). The Notes were priced at 99.211% of the principal amount and will mature on December 1, 2030. Proceeds of the Notes were used to fund acquisitions, development and redevelopment activities, and the repayment of the Company’s $100 million term loan due in 2022.

In December, the Company completed a common stock offering issuing 6,900,000 shares of its common stock, including 900,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares at a net price of $47.15 per share. The Company received proceeds of approximately $325.3 million, before deducting offering expenses. Proceeds of the offering are being used to fund acquisition, development and redevelopment activities, and for general corporate purposes. 

During the fourth quarter, the Company issued an aggregate of 709,981 shares of common stock through its at-the-market equity offering program (“ATM program”) at an average price of $50.13 per share, receiving proceeds of approximately $35.6 million before issuance costs. On November 9, 2020, the Company renewed its ATM program to include $750 million of capacity with the option to offer shares on a forward basis.  As of December 31, 2020, the renewed ATM program had approximately $720.7 million of remaining capacity. 

As of December 31, 2020, Rexford had a cash balance of approximately $176 million and zero outstanding balance under its $500 million revolving credit facility.  The Company has no debt maturities through 2022.

Fourth Quarter Earnings Release:

The Company will release audited fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 10, 2021. A conference call will be held on Thursday, February 11, 2021, at 1:00 p.m. Eastern Time to review the Company’s fourth quarter results, discuss recent events and conduct a question-and-answer period. The conference call will be available on the Company’s website at ir.rexfordindustrial.com.

To Participate in the Telephone Conference Call:
Dial in at least 5 minutes prior to start time:
Domestic: 1-877-407-0789
International: 1-201-689-8562

Conference Call Playback:
Domestic: 1-844-512-2921
International: 1-412-317-6671
Pass code: 13714732
The playback can be accessed through March 11, 2021.

About Rexford Industrial:

Rexford Industrial, a real estate investment trust focused on owning and operating industrial properties throughout Southern California infill markets, owns 249 properties with approximately 31.5 million rentable square feet and manages an additional 20 properties with approximately 1.0 million rentable square feet.

For additional information, visit www.rexfordindustrial.com.

Contact:
Investor Relations:

Stephen Swett

424-256-2153 ext 401
[email protected]

View original content:http://www.prnewswire.com/news-releases/rexford-industrial-announces-fourth-quarter-and-full-year-2020-operating-results-transaction-and-capital-markets-activity-301205141.html

SOURCE Rexford Industrial Realty, Inc.

TEL AVIV, Israel and RALEIGH, N.C,, Jan. 11, 2021 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or “the Company”), a specialty biopharmaceutical company, today reported that its partner, Cosmo Pharmaceuticals (SIX: COPN) (“Cosmo”), announced that it had successfully completed their Phase 2 Proof-of-Concept (POC) clinical trial of Rifamycin SV-MMX 600mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). 

As part of an exclusive license agreement between RedHill and Cosmo from October 2019 for the U.S. rights to Aemcolo^® (rifamycin), RedHill maintains certain rights, including a right of first refusal, in relation to Rifamycin SV-MMX 600 mg in the U.S.

Designed to address the debilitating effects of IBS-D, Rifamycin SV-MMX is delivered at a 600mg dose and with different release features to Aemcolo^®. Aemcolo^® is approved for travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli (E. coli) in adults and promoted by RedHill for such use in the U.S.

Cosmo reported that results of the Phase 2 POC study show the achievement of statistical significance in all the study populations (ITT, FAS, m-FAS and PP) for the composite primary endpoint (substantial pain and diarrhea decrease) [OR 3.26 (1.39 – 7.67); p-value 0.0066] and for most secondary endpoints such as adequate relief of IBS-related symptoms [OR 2.18 (1.12 – 4.26); p-value 0.0227] and IBS-related bloating at the end of treatment period [OR 2.13 (1.11 – 4.07); p-value 0.0223].

“We are delighted for our partner, Cosmo, on the positive outcome of this study, which clearly demonstrates the potential for Rifamycin SV-MMX 600mg, if approved, to be an important treatment option in tackling IBS-D,” said Dror Ben-Asher, RedHill’s CEO.

About Aemcolo^® (rifamycin)

Aemcolo^® (rifamycin) is an orally-administered, delayed-release, non-systemic antibiotic approved for the treatment of travelers’ diarrhea caused by non-invasive strains of Escherichia coli (E. coli) in adults. Aemcolo^® is the first antibiotic engineered with Cosmo Pharmaceuticals’ Multi Matrix Technology (MMX^®). MMX technology is designed to deliver the active pharmaceutical ingredients in a delayed and controlled manner directly to the lower intestine.

INDICATION AND IMPORTANT SAFETY INFORMATION

Aemcolo^® is indicated for the treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli) in adults.

Limitations of Use

Aemcolo^® is not indicated in patients with diarrhea complicated by fever or bloody stool or due to pathogens other than noninvasive strains of E. coli.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Aemcolo^® and other antibacterial drugs, Aemcolo^® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

CONTRAINDICATION

Aemcolo^® is contraindicated in patients with a known hypersensitivity to rifamycin, any of the other rifamycin class antimicrobial agents, or any of the components in Aemcolo^®.

WARNINGS AND PRECAUTIONS

Risk of Persistent or Worsening Diarrhea Complicated by Fever and/or Bloody Stool

Aemcolo^® was not shown to be effective in patients with diarrhea complicated by fever and/or bloody stool or diarrhea caused by pathogens other than E. coli and is not recommended for use in such patients.

Discontinue Aemcolo^® if diarrhea gets worse or persists more than 48 hours and consider alternative antibacterial therapy.

Clostridium difficile

–
Associated Diarrhea (CDAD)

CDAD has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.

Consider CDAD in all patients who present with diarrhea following antibacterial drug use. Careful

medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

Development of Drug-Resistant Bacteria

Prescribing Aemcolo^® in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

ADVERSE REACTIONS

Discontinuation of Aemcolo^® due to adverse reactions occurred in 1% of patients. The most frequent adverse reactions were abdominal pain (0.5%) and pyrexia (0.3%).

Adverse reactions that occurred in at least 2% of Aemcolo^®-treated patients and with a higher incidence than in the placebo or ciprofloxacin groups were constipation 3.5% and headache 3.3%, respectively.

USE IN SPECIFIC POPULATIONS

Pregnancy

There are no available data on AEMCOLO use in pregnant women to inform any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes.

Lactation

There is no information regarding the presence of AEMCOLO in human milk, the effects on the breastfed infant, or the effects on milk production.

Pediatric Use

The safety and effectiveness of AEMCOLO has not been established in pediatric patients <18 years of age.

See Full prescribing information for Aemcolo^® is available at www.aemcolo.com 

To submit adverse event reports or product complaint reports, contact RedHill Biopharma, Inc. at 1(833)-ADR-HILL. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

About RedHill Biopharma

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik^® for opioid-induced constipation in adults^[1], Talicia^®for the treatment of Helicobacter pylori (H. pylori) infection in adults^[2], and Aemcolo^® for the treatment of travelers’ diarrhea in adults^[3]. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) opaganib (Yeliva^®), a first–in–class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (iv) RHB-102 (Bekinda^®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v) RHB-107 (upamostat), a Phase 2-stage serine protease inhibitor with a planned Phase 2/3 study in symptomatic COVID-19 and targeting multiple other cancer and inflammatory gastrointestinal diseases; and (vi) RHB–106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com / https://twitter.com/RedHillBio.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation risks related to the commencement or the timing of our clinical trials with RHB-102 (Bekinda^®) and ABC294640 (Yeliva^®), as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its therapeutic candidates; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates and Talicia^®; (v) the Company’s ability to successfully commercialize and promote Talicia^®,
Aemcolo

^®

, and Movantik

^®
 ; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company’s Expanded Access Program; (xiv) competition from other companies and technologies within the Company’s industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on February 26, 2019, as amended on May 15, 2019. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

[1] Full prescribing information for Movantik^® (naloxegol) is available at: www.Movantik.com.  

[2] Full prescribing information for Talicia^® (omeprazole magnesium, amoxicillin and rifabutin) is available at: www.Talicia.com.       

[3] Full prescribing information for Aemcolo^® (rifamycin) is available at: www.Aemcolo.com.

Logo – https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg

 

 

 

View original content:http://www.prnewswire.com/news-releases/redhills-partner-cosmo-pharmaceuticals-successfully-completes-phase-2-study-of-rifamycin-sv-mmx-600mg-in-ibs-d-301205143.html

SOURCE RedHill Biopharma Ltd.

TOKYO and CAMBRIDGE, England, Jan. 11, 2021 /PRNewswire/ — Sosei Group Corporation (“the Company”;) (TSE: 4565), today announced its Chief Financial Officer, Chris Cargill, will present at the 39th Annual J.P. Morgan Healthcare Conference, which will take place virtually, on Thursday, 14 January 2021.

The presentation will begin at 10:00 a.m. Eastern Standard Time, and will be video broadcasted live in English to registered conference attendees via the Digital Conference Book. For non-attendees, an audio link to the Company’s virtual session presentation can be accessed here. Presentation slides will be made available through the investor section of the Company’s Home Page, www.soseiheptares.com. https://jpmorgan.metameetings.net/events/healthcare19/sessions/23813-sosei-heptares/webcast

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world’s leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

For more information, please visit https://www.soseiheptares.com/

LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco

Enquiries:

Sosei Heptares – Media and Investor Relations
Hironoshin Nomura, SVP Investor Relations and Corporate Strategy
+81 (0)3 6679 2178 | [email protected]

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
+81 (0)3 5210 3399 | [email protected]

Citigate Dewe Rogerson (for Sosei Heptares)

Yas Fukuda – Japanese Media
+81 (0)3 4360 9234 | [email protected]

Mark Swallow, David Dible – International Media
+44 (0)20 7638 9571 | [email protected]

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

View original content:http://www.prnewswire.com/news-releases/sosei-heptares-to-present-at-39th-annual-jp-morgan-healthcare-conference-301205129.html

SOURCE Sosei Heptares

ROCKVILLE, Md., Jan. 11, 2021 /PRNewswire/ — CEVA, Inc. (NASDAQ: CEVA), the leading licensor of wireless connectivity and smart sensing technologies, will announce results for the fourth quarter and full year 2020 on February 16, 2021 before the NASDAQ market opens.

Following the release, CEVA management will conduct a conference call at 8:30 a.m. Eastern Time to discuss the operating performance for the quarter.

The conference call will be available via the following dial in numbers:

• U.S. Participants: Dial 1-844-435-0316 (Access Code: CEVA)
• International Participants: Dial +1-412-317-6365 (Access Code: CEVA)

The conference call will also be available live via webcast at the following link: https://www.webcaster4.com/Webcast/Page/984/39449. Please go to the web site at least fifteen minutes prior to the call to register, download and install any necessary audio software.

For those who cannot access the live broadcast, a replay will be available by dialing +1-877-344-7529 or +1-412-317-0088 (access code: 10151090) from one hour after the end of the call until 9:00 a.m. (Eastern Time) on February 23, 2021. The replay will also be available at CEVA’s web site www.ceva-dsp.com.

About CEVA, Inc.
CEVA is the leading licensor of wireless connectivity and smart sensing technologies. We offer Digital Signal Processors, AI processors, wireless platforms and complementary software for sensor fusion, image enhancement, computer vision, voice input and artificial intelligence, all of which are key enabling technologies for a smarter, connected world. We partner with semiconductor companies and OEMs worldwide to create power-efficient, intelligent and connected devices for a range of end markets, including mobile, consumer, automotive, robotics, industrial and IoT. Our ultra-low-power IPs include comprehensive DSP-based platforms for 5G baseband processing in mobile and infrastructure, advanced imaging and computer vision for any camera-enabled device and audio/voice/speech and ultra-low power always-on/sensing applications for multiple IoT markets. For sensor fusion, our Hillcrest Labs sensor processing technologies provide a broad range of sensor fusion software and IMU solutions for AR/VR, robotics, remote controls, and IoT. For artificial intelligence, we offer a family of AI processors capable of handling the complete gamut of neural network workloads, on-device. For wireless IoT, we offer the industry’s most widely adopted IPs for Bluetooth (low energy and dual mode), Wi-Fi 4/5/6 (802.11n/ac/ax) and NB-IoT. Visit us at https://www.ceva-dsp.com/ and follow us on Twitter, YouTube,Facebook, LinkedIn and Instagram.

Logo: https://mma.prnewswire.com/media/74483/ceva__inc__logo.jpg

View original content:http://www.prnewswire.com/news-releases/ceva-inc-schedules-fourth-quarter-and-full-year-2020-earnings-release-and-conference-call-301204948.html

SOURCE CEVA, Inc.

PITTSBURGH, Jan. 11, 2021 /PRNewswire/ —

/ Key Highlights

• Navantia and Ansys are significantly reducing the development time and increasing the performance of next-generation navy ships including F-110 frigates and S80 submarines
• Through a new strategic agreement, Navantia engineers will use Ansys’ solutions to support the Shipyard 4.0 Integrated Business Management System — Navantia’s cutting-edge technology platform that incorporates digital technologies across the operational lifecycle of its vessels

Navantia and Ansys (NASDAQ: ANSS) are substantially decreasing the design time and boosting the performance of next-generation navy vessels, such as F-110 frigates and S-80 submarines. Through a new strategic agreement, Navantia engineers will leverage Ansys’ solutions as part of the Shipyard 4.0 Integrated Business Management System — Navantia’s leading-edge technology platform that includes digital technologies across the operational lifecycle of navy ships to improve product quality and speed production.

To enhance ship design, maximize construction speed and minimize development costs, engineering processes and procedures must ensure that simulation tools and data are fused across the enterprise digital ecosystem and throughout a vessel’s lifecycle. This collaboration equips Navantia engineers with Ansys’ comprehensive suite of simulation solutions to spur the development of highly advanced frigates and submarines — significantly lessening vessel signatures, decreasing the impact of external and environmental threats and producing lightweight and optimized components.

Integrating Ansys’ solutions drastically improves Navantia’s simulation process and data management capabilities and automates engineering workflows across Navantia’s digital thread to heighten operational efficiency. Additionally, physics-based digital twins will help ship engineers monitor performance and maintenance requirements of deployed vessels, helping to promote the safety and productivity of naval warfighters.

“Ansys is furthering Shipyard 4.0’s mission by providing industry-leading simulation solutions and digital twin technology to our entire digital enterprise. This serves as a formidable force multiplier for increasing our innovation capacity and represents a dynamic new direction for engineering smart products and services,” said Donato Martinez, chief technology officer at Navantia. “Under this new agreement, Ansys will empower our engineers to create a multitude of bold new designs, improve simulation fidelity, dramatically boost product performance and cut development time and cost.”

“Together with Navantia, we are building highly advanced smart ships that provide lifesaving abilities,” said Prith Banerjee, chief technology officer at Ansys. “Ansys will support Navantia by enhancing a clear digitization strategy within an open environment and enabling a robust shared knowledge infrastructure for their engineering teams, which will improve collaboration. Additionally, Ansys solutions will drive engineering productivity, creating highly efficient workflows that were inconceivable only a few years ago.”

/ About Ansys

If you’ve ever seen a rocket launch, flown on an airplane, driven a car, used a computer, touched a mobile device, crossed a bridge or put on wearable technology, chances are you’ve used a product where Ansys software played a critical role in its creation. Ansys is the global leader in engineering simulation. Through our strategy of Pervasive Engineering Simulation, we help the world’s most innovative companies deliver radically better products to their customers. By offering the best and broadest portfolio of engineering simulation software, we help them solve the most complex design challenges and create products limited only by imagination. Founded in 1970, Ansys is headquartered south of Pittsburgh, Pennsylvania, U.S.A. Visit www.ansys.com for more information.

Ansys and any and all ANSYS, Inc. brand, product, service and feature names, logos and slogans are registered trademarks or trademarks of ANSYS, Inc. or its subsidiaries in the United States or other countries. All other brand, product, service and feature names or trademarks are the property of their respective owners.

ANSS–C

/ Contacts

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/navantia-leverages-ansys-digital-transformation-solutions-to-design-next-gen-naval-vessels-301203282.html

SOURCE Ansys

REDWOOD CITY, Calif., Jan. 11, 2021 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its preliminary, unaudited revenue for the fourth quarter and full-year ended December 31, 2020.

Fourth Quarter 2020

Preliminary, unaudited fourth quarter 2020 worldwide revenue is expected to be $109.7 million, compared to $114.4 million in the fourth quarter in the prior year period. Preliminary, unaudited fourth quarter 2020 U.S. revenue is expected to be $94.6 million, compared to $97.9 million in the prior year period. Preliminary, unaudited fourth quarter 2020 international revenue is expected to be $15.1 million, compared to $16.5 million in the prior year period. Fourth quarter U.S. trial procedures were down approximately 8% versus prior year. 

Full-Year 2020

Nevro’s preliminary, unaudited full year 2020 worldwide revenue is expected to be $362.0 million, compared to $390.3 million in the prior year period. Preliminary, unaudited full year U.S. revenue is expected to be $311.9 million, compared to $326.0 million in the prior year period. Preliminary, unaudited full year international revenue is expected to be $50.2 million, compared to $64.3 million in the prior year period.

“Despite the challenges created by the COVID-19 pandemic in 2020, I am extremely proud of the significant efforts of the Nevro team to serve our customers and patients, and execute on our plans for the future,” said D. Keith Grossman, Chairman, CEO and President of Nevro.  “In the second half of the fourth quarter, the increase in COVID activity negatively affected both trial and permanent implant volumes.  Even with the pandemic challenges throughout the year, we continued to capture share in the core lower back and leg pain market with our best-in-class SCS technology, superior clinical data and sharpened execution.  I believe we are well positioned for attractive growth when the pressure of COVID on our business subsides.  In addition, we are excited about expanded growth opportunities to treat Painful Diabetic Neuropathy and Non-Surgical Refractory Back Pain, which will bring our HF10 therapy to the many patients who are unable to find relief with currently available treatment options.”

Nevro plans to report its full financial results and provide more detail for its fourth quarter and full-year 2020 financial results after the market closes on Wednesday, February 24, 2021, to be followed by its quarterly conference call at 1:30 pm Pacific Time that day.

Nevro to Present at J.P. Morgan Healthcare Conference

D. Keith Grossman, Chairman, CEO and President of Nevro, will present at the J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 4:30 pm Eastern Time / 1:30 pm Pacific Time.  A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro’s website at www.nevro.com. 

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.nevro.com.  The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro Corp. 

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro’s proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: the company’s expectations for its fourth quarter and full year 2020 worldwide, U.S. and international revenue; our belief that we are well positioned for attractive growth when the pressure of COVID on our business subsides; and our excitement about expanded growth opportunities to treat Painful Diabetic Neuropathy and Non-Surgical Refractory Back Pain. These forward-looking statements are based upon information that is currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; our ability to manufacture our products to meet demand; the level and availability of third-party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K filed on February 25, 2020 and our Quarterly Report on Form 10-Q filed on November 5, 2020, as well as any reports that we may file with the Securities and Exchange Commission in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Our preliminary operating results for the quarter and full year ended December 31, 2020 are subject to adjustment as we complete our year-end audit and other processes and are not necessarily indicative of our operating results for any future periods.

Amounts may not add due to rounding.

Investors and Media:

Julie Dewey, IRC
Nevro Corp.
Vice President, Investor Relations & Corp Communications
650-433-3247  |  [email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-announces-preliminary-unaudited-fourth-quarter-and-full-year-2020-revenue-301204937.html

SOURCE Nevro Corp.

LISTING: TORONTOSTOCK EXCHANGE
SYMBOL: BDT

MISSISSAUGA, ON
, Jan. 11, 2021 /CNW/ – Bird Construction Inc. (TSX: BDT) announced today that its wholly owned subsidiary, Stuart Olson Construction Ltd., has been awarded a $154 million design-build contract for the Nanaimo Correctional Centre (NCC) Replacement Project in Nanaimo, British Columbia. Bird previously announced being selected as the preferred proponent late last year. The Stuart Olson Construction Ltd. design-build team includes the local expertise of 17 collaborating partners.

The NCC Replacement Project features modernized spaces for educational, vocational and certified trades training in addition to rehabilitative and culturally responsive Indigenous programming. It also includes Vancouver Island’s first provincial custody capacity for women. The two local First Nations, Snuneymuxw and Snaw’Naw’As, will also have input into the design as well as job and contract opportunities during construction.

Design activities are expected to commence in January 2021, with pre-construction proceeding in the first quarter of 2021.

“This project is one that demonstrates a strong fit for our institutional portfolio in British Columbia as well as an important and valuable piece of infrastructure for the community,” said Mr. Teri McKibbon, President and CEO of Bird. “We look forward to working with our partners and the local community to successfully deliver this infrastructure project.”

This press release contains forward-looking information (as defined in applicable Canadian securities
legislation) that involves known and unknown risks, uncertainties and other factors which may cause
actual results, performance, or achievements to materially differ from those expressed or implied by
the forward-looking information.

The Toronto Stock Exchange does not accept responsibility for the adequacy or accuracy of this release. 

About Bird Construction
Bird (TSX:BDT) is a leading Canadian construction company operating from coast-to-coast and servicing all of Canada’s major markets. Bird provides a comprehensive range of construction services from new construction for industrial, commercial, and institutional markets; to industrial maintenance, repair and operations services, heavy civil construction, and contract surface mining; as well as vertical infrastructure including, electrical, mechanical, and specialty trades. For over 100 years, Bird has been a people-focused company with an unwavering commitment to safety and a high level of service that provides long-term value for all stakeholders. www.bird.ca

SOURCE Bird Construction Inc.